M
Medicago
Research and development of vaccines and treatments using plant-based technology
About Medicago
Medicago is a biotechnology company specializing in the development of plant-based vaccines and therapeutics. The company leverages a unique discovery and development platform that is both scalable and versatile, enabling the creation of a robust and limitless product pipeline. Medicago operates in the global healthcare market, primarily serving governments, healthcare providers, and pharmaceutical companies. The business model focuses on research and development, clinical trials, and commercialization of its proprietary products. Revenue is generated through partnerships, licensing agreements, and direct sales of its vaccines and therapeutics. Medicago's approach is particularly relevant in addressing urgent global health challenges, including pandemics and emerging infectious diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1997
- Headquarters
- Quebec City, Canada
- Listing
- IPO 2006
- Employees
- 194
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Molecular Biology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Oct 2020 | $127M | — | Government of Canada · Innovation, Science and Economic Development Canada | ↗ |
| GRANTOther financing | Mar 2020 | $5.1M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $4.1M | 0% |
| 2025 | $4.1M | 0% |
| 2024 | $4.1M | 0% |
| 2023 | $4.1M | 0% |
| 2022 | $4.1M | 0% |
| 2021 | $4.1M | 0% |
| 2020 | $4.1M | — |
Growth signals
Latest recorded traffic for Medicago is 860 monthly website visits, up 115% over the last three months. Medicago's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Government of Canada
Innovation, Science and Economic Development Canada
Series A1 investor entered at this stage
Yorkville Advisors
Other known investors1 additional known investor
Mitsubishi Tanabe Pharma
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medicago on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medicago’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.